Multiple Ascending Dose Study of BMS-582949 in Patients With Stable Rheumatoid Arthritis on the Methotrexate Background

Completed · Phase 1

Conditions studied: Rheumatoid Arthritis

In brief

The purpose of this clinical research study is to learn if it is safe for rheumatoid arthritis patients to take BMS-582949 along with methotrexate.

Key facts

Study ID

NCT00162292

Run by

Bristol-Myers Squibb

People needed

33

Starts

2005-11-01

Expected to finish

2007-10-01

Last updated by the study team

2010-03-02

Who can join

Age: 18 and older, up to 70. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Age 18-70 years
• Diagnosis of RA for ≥6 months
• Swollen or tender joint or ESR >ULN. Subject must be on stable doses of MTX
• Women of Childbearing Potential

You may not qualify if…

• Serum transaminase levels >ULN
• CK>ULN
• Cannot have taken Orencia or Remicade within 8 weeks of baseline, Humira or Enbrel within 4 weeks of baseline
• Use of H2 blockers or Proton Pump inhibitors while on study

Where it is running

• Desert Medical Advances — Palm Desert, California, United States
• Boling Clinical Trials — Upland, California, United States
• Delray Research Associates — Delray Beach, Florida, United States
• Ocala Rheumatology Research Center — Ocala, Florida, United States
• Phase Iii Clinical Research — Fall River, Massachusetts, United States
• Covance Clinical Research Unit Inc. — Dallas, Texas, United States
• Radiant Research San Antonio Northeast — San Antonio, Texas, United States
• Healthcare Discoveries, Inc — San Antonio, Texas, United States
• Local Institution — León, Guanajuato, Mexico
• Local Institution — Metepec, State of Mexico, Mexico

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.